by Raynovich Rod | Apr 26, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 4/29 12:15p Mid-day trading -Healthcare weak as Investors rebalance to other sectors. Gilead Sciences (GILD) up over 6% and. boosts overall market with positive remdesivir data. NAZ up 2.84%, IBB up 1.3%, IJR break-out? Technology, financials and energy show...
by Raynovich Rod | Apr 4, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Coronavirus (COVID-19) is an infectious disease currently spreading across the globe. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover. Others (particularly elderly people and those with underlying medical...
by Raynovich Rod | Mar 8, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
3/30 11;30a Major news on COVID-19 diagnostics spark rally. Abbott launches 5 minute test. ABT up 7.28% ,JNJ up 6.8%, all large caps up, IBB up 2.55, XBI up 1.61%. Risk reward still looks good for biotech by year-end 2020. See IBB 2 yr chart below. ======== 3/27 After...
by Raynovich Rod | Mar 2, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 nice broad biotech rally on stimulus hopes with biotech now seen as possible solution https://www.barrons.com/articles/the-dow-is-up-900-points-after-congress-agrees-on-8-3-billion-package-to-battle-coronavirus-51583350527?mod=hp_LATEST XBI up over 3%to $93...
by Raynovich Rod | Jan 16, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Momentum is Easing in Biotech -Is the JPMorgan rally Over? We need to see which stocks hold up when momentum decelerates. it has been a good run for the week but not too frothy.We are “content challenged” in that we sat through three days of interesting...
by Raynovich Rod | Jan 14, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPM Notes #2 : Investors buy into Life science innovation After a lackluster day Monday the tape for JPM life science sector stocks picked up with a decent rally. Major ETFs reversed the trend from yesterday with the IBB up 1.64% and the XBI up 2.94% despite NASDAQ...
by Raynovich Rod | Jan 13, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 1/14/2 12:30 EDT…Very Bullish Tape today–Update at Close IBB up 1.27% , XBI up 2.47%. Gene therapy stocks are on a tear even before BLUE and EDIT (both up >5%) present later today and tomorrow. ===== J.P.Morgan Healthcare Conference Notes #1:...
by Raynovich Rod | Nov 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on...
by Raynovich Rod | Oct 31, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 Genmark (GNMK) down 3.6 % to $5.61 on Q3 results. Beat on revenue to $20.9 M up 32 % over prior quarter, loss of 20 cents/share.Waiting for a buy-out in 2020? Update-1 …Nov. 1…All of these picks are up today, IWM is up 1.6%, IJR is up...
by Raynovich Rod | Oct 23, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/25 at close…A Good Day on Low Volume-NASDAQ up 0.7%, S&P is up 20.56% YTD! Large caps mixed with IBB down a tad 0.29%;leaders are BIIB,BMY,RHHBY NASDAQ-100 at record high; QQQ up 0.8% to $195.64. Gilead Sciences (GILD) a big loser on earnings...
